NeuroSearch A/S   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Ballerup Denmark (1989)
Status: Defunct (2012)

Organization Overview

First Clinical Trial
2003
NCT00467428
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

A Carlsson Research AB | Arvid Carlsson Research AB | NsGene A/S

Active Ingredients

Drugs in Phase 3 Trials (1)

pridopidine (1 trial)

Drugs in Phase 2 Trials (5)

gsk372475 (1 trial)

lidocaine (xylocaine) (1 trial)

ns1209 (1 trial)

osu 6162 (3 trials)

tesofensine (3 trials)

Drugs in Phase 1 Trials (2)

acr325 (1 trial)

cenegermin-bkbj (oxervate) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 1)

Attention Deficit Disorder with Hyperactivity (Phase 2)

Huntington Disease (Phase 3)

Hyperkinesis (Phase 2)

Neuralgia (Phase 2)

Obesity (Phase 2)

Parkinson Disease (Phase 1)

Stroke (Phase 2)

Weight Loss (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial APIs: 8